Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

New ways of exploiting medicinal uses of cannabis

Research exploring new ways of exploiting the full medicinal uses of cannabis while avoiding unwanted side-effects will be presented to pharmacologists Tuesday, 15 July by leading scientists attending the Federation of European Pharmacological Societies Congress, EPHAR 2008.

From The University of Manchester 15 Jul 2008

Cymbalta approved for fibromyalgia

The U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company announced.

16 Jun 2008

Improving palliative care

Palliative care clinicians are increasingly faced with the problem of treating a wider range of diseases, and treating patients in all settings, not just in hospices or specialist units. This has created new challenges in the treatment of symptoms, which in turn creates a need for new research and practical recommendations to help palliative care clinicians and improve patient care.

2 Jun 2008

Antidepressant amitriptyline shown to alleviate symptoms of irritable bowel syndrome

Researchers at Mattel Children's Hospital UCLA have found that low-dose antidepressant therapy can significantly improve the overall quality of life for adolescents suffering from irritable bowel syndrome (IBS).

1 May 2008

Trauma patients likely to experience moderately severe pain 1 year after injuries

Most patients have moderately severe pain resulting from their injuries one year after sustaining major trauma, according to a report in the March issue of Archives of Surgery, one of the JAMA/Archives journals.

18 Mar 2008

M. D. Anderson, AstraZeneca form alliance to advance understanding of cancer-related pain

The University of Texas M. D. Anderson Cancer Center and AstraZeneca (NYSE:AZN) today announced that they will collaborate to help advance understanding of neuropathic pain caused by cancer chemotherapy, a side effect that often limits optimal therapeutic dosing in cancer treatments.

25 Jan 2008

Pain treatment in the field: Good for soldiers' comfort and better for rebuilding troop strength

Noncombat-related acute and recurrent chronic pain are the leading causes of soldier attrition in modern war, with the return-to-duty rate as low as 2 percent when these soldiers are treated outside the theaters of operation.

18 Dec 2007

Carbamazepine based drugs to include new advice for patients with Asian ancestry

The U.S. Food and Drug Administration today announced that the manufacturers of drugs containing the active ingredient carbamazepine have agreed to add to the drugs' labeling a recommendation that, before starting therapy with the drugs, patients with Asian ancestry get a genetic blood test that can identify a significantly increased risk of developing a rare, but serious, skin reaction.

13 Dec 2007

sLRP1-alpha provides relief from neuropathic pain

Injury to peripheral nerves (the causes of which include shingles, HIV-AIDS, toxins, alcoholism, repetitive motion disorders, surgery, and cancer) causes neuropathic pain, which differs from ordinary pain and is usually perceived as a steady burning, pins and needles, electric shock sensations, and/or tickling.

4 Dec 2007

FDA approves Cymbalta for maintenance treatment of major depressive disorder

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

2 Dec 2007

New non-addictive pain-killers

Two University of Adelaide pharmacologists working with one the world's leading neuroscientists have helped pave the way for the development of new pain-killing drugs that are not addictive.

20 Nov 2007

EpiCept to conduct Phase III study of EpiCept NP-1 for treatment of chemotherapy induced peripheral neuropathy

EpiCept Corporation has announced that it will study EpiCept NP-1, its patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine, for the treatment of chemotherapy induced peripheral neuropathy (CPN) in the ATTRACT-CPN Phase III Study (Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy).

23 Jul 2007

Gene therapy provides hope for peripheral neuropathy

Researchers from the University of Pittsburgh School of Medicine report that they have successfully used gene therapy to block the pain response in an animal model of neuropathic pain, a type of chronic pain in people for which there are few effective treatments.

1 Jun 2007

Pulsed radiofrequency treatment for chronic back pain

Chronic back pain is a condition that affects a significant part of the population, with patients falling into three major groups; those with herniated discs, spinal stenosis (a nerve affecting narrowing of the spinal cord), and complications from failed back surgery.

22 May 2007

Identifying cardiorespiratory neurocircuitry involved in central command during exercise in humans

For almost one hundred years the brain's ,central command, system , whose charge includes controlling the body's cardiorespiratory response to exercise , has been pursued. Animal experiments and functional imaging studies have provided clues to the location of this system, but the underlying electrophysiological activity has never been measured.

30 Apr 2007

Talk beyond pain: Understanding diabetic nerve pain

Results from a new survey of more than 600 physicians who treat diabetic peripheral neuropathic pain, or diabetic nerve pain, reveal that nearly all (97 percent) believe that the condition is often misdiagnosed.

20 Apr 2007

Eslicarbazepine shows promise for treating epileptic seizures

A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications.

7 Apr 2007

UT Metroplex institutions to collaborate on biomedical research

Researchers from the three University of Texas campuses in the Dallas-Fort Worth metropolitan area are combining their expertise in biomedical science, engineering and physical sciences on projects aimed at solving real-world medical problems.

5 Apr 2007

FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder (GAD), a condition that affects more than 6.5 million American adults in a given year.

26 Feb 2007

New ANS spinal cord stimulation lead for patients with low back pain

St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) clearance of two spinal cord stimulation tripolar paddle leads for use with the Renew Neurostimulation System.

15 Feb 2007